Tipping Points and Endogenous Determinants of Nigrostriatal Degeneration by MPTP

Trends Pharmacol Sci. 2017 Jun;38(6):541-555. doi: 10.1016/j.tips.2017.03.010. Epub 2017 Apr 23.

Abstract

The neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes a Parkinson's disease (PD)-like syndrome by inducing degeneration of nigrostriatal dopaminergic neurons. Studies of the MPTP model have revealed the pathomechanisms underlying dopaminergic neurodegeneration and facilitated the development of drug treatments for PD. In this review, we provide an update on MPTP bioactivation and biodistribution, reconcile the distinct views on energetic failure versus reactive oxygen species (ROS) formation as main drivers of MPTP-induced neurodegeneration, and describe recently identified intrinsic features of the nigrostriatal system that make it particularly vulnerable to MPTP. We discuss these new perspectives on the endogenous tipping points of tissue homeostasis and the drivers responsible for vicious cycles in relation to their relevance for the development of novel intervention strategies for PD.

Keywords: MPDP(+); MPP(+); Parkinson’s disease; astrocytes; autoxidation.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacokinetics
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology*
  • Animals
  • Astrocytes / drug effects
  • Astrocytes / metabolism
  • Astrocytes / pathology
  • Dopaminergic Neurons / drug effects
  • Dopaminergic Neurons / metabolism
  • Dopaminergic Neurons / pathology
  • Humans
  • MPTP Poisoning / chemically induced*
  • MPTP Poisoning / metabolism
  • MPTP Poisoning / pathology
  • Neostriatum / drug effects
  • Neostriatum / metabolism
  • Neostriatum / pathology
  • Neurodegenerative Diseases / chemically induced*
  • Neurodegenerative Diseases / metabolism
  • Neurodegenerative Diseases / pathology

Substances

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine